What is Zacks Research's Forecast for ESPR FY2025 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at Zacks Research lifted their FY2025 EPS estimates for Esperion Therapeutics in a report released on Thursday, July 10th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.42) for the year, up from their previous estimate of ($0.43). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q1 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.24) EPS, Q1 2027 earnings at ($0.19) EPS and Q2 2027 earnings at $0.05 EPS.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. The business had revenue of $65.00 million during the quarter, compared to the consensus estimate of $54.97 million.

A number of other analysts have also recently issued reports on ESPR. Needham & Company LLC reduced their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group reduced their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR traded up $0.12 during midday trading on Monday, reaching $1.24. The stock had a trading volume of 3,626,175 shares, compared to its average volume of 4,686,217. The stock has a 50-day moving average of $1.03 and a 200-day moving average of $1.40. The company has a market capitalization of $245.77 million, a price-to-earnings ratio of -1.55 and a beta of 0.70. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors have recently bought and sold shares of the stock. Cibc World Markets Corp purchased a new position in Esperion Therapeutics during the fourth quarter valued at $39,000. Meridian Wealth Management LLC purchased a new position in Esperion Therapeutics during the first quarter valued at $29,000. North Star Investment Management Corp. purchased a new position in Esperion Therapeutics during the second quarter valued at $25,000. Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics during the second quarter valued at $25,000. Finally, Crestline Management LP purchased a new position in Esperion Therapeutics during the fourth quarter valued at $63,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.